EN DE
Watch CHEMO PHARMA LABORATORIES LTD. for free: once a week we email you where price and fair value stand.
Data-driven stock valuation

CHEMO PHARMA LABORATORIES LTD. (CHEMOPH) fair value: what the stock is really worth

As of Nov 18, 2026: fair value (intrinsic value) of CHEMO PHARMA LABORATORIES LTD. stock ₹50.19, price ₹92.00, that is 45.4% below the price, quality 64 out of 100. Rating: strongly overvalued. Calculated from audited financials with 8 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare IN · ISIN INE320M01019

CP CHEMO PHARMA LABORATORIES LTD. logo Thin data Nov 15, 2026

CHEMO PHARMA LABORATORIES LTD.

CHEMOPH · BSE

Far too expensive (fair value 45% below the price) and price moving sideways, but solid company: meets 1 of 3 rules.

Follow free in the weekly email
Quality 64/100 
Price moving sideways (no uptrend) 
Mixed vs. peers (4/8) 
Revenue last quarter 17% below a year ago. 
Fair value ₹50.19 · Strongly overvalued 
Negative free cash flow 
Narrow moat 29/100 · thin data
Thin data 
⚠ Thinly traded
Watch CHEMO PHARMA LABORATORIES LTD. for free: once a week we email you where price and fair value stand. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

₹150.65 ₹17.85 Fair Value ₹50.19 Apr 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 15, 2026.

How to read this chart

60‑month range ₹17.85 – ₹150.65 · fair‑value band ₹37.64 – ₹59.37 · the ₹92.00 price screens above the ₹50.19 fair value. As of Nov 15, 2026.

Follow CHEMO PHARMA LABORATORIES in your weekly email

Every Wednesday you see whether CHEMO PHARMA LABORATORIES is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Chemo Pharma Laboratories Limited does not have significant operations. Previously, the company was engaged in the finance and investment activities. Chemo Pharma Laboratories Limited was incorporated in 1942 and is based in Mumbai, India.

Stock analysis

CHEMO PHARMA LABORATORIES LTD. (CHEMOPH) currently trades at ₹92.00, while our model-based Fair Value estimate is ₹50.19, 45% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Multiples group reads highest at a median of ₹222.27 per share, and 1 of the 8 models we run sit above the ₹92.00 price.

Bear case: the Earnings-Based group reads lowest at ₹11.41, and 7 of the 8 models stay below the price. Data coverage for this calculation is low.

Scenario range: ₹37.64 (bear) to ₹59.37 (bull), the price of ₹92.00 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 64/100 (solid quality), in the Healthcare sector.

CHEMO PHARMA LABORATORIES LTD. reported revenue of ₹0 in FY2025 versus ₹0 in FY2021. Reported net income was ₹3.4M in FY2025, compounding +8.2%/yr from FY2021.

Key figures

Market cap ₹196M (≈ $2.1M) Micro · P/S ratio 84.1 · EPS (TTM) ₹−81.48 · Return on equity −162% · Return on assets (EBIT) −1.8% (5-year average) · Operating margin 18.7% · Revenue (TTM) ₹2.3M · Revenue growth (YoY) −16.7%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 29 out of 100 (low confidence).

What moves the price

The share trades about 37% below its 52-week high and 30% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −6% fair-value upside, at −45%, CHEMOPH screens richer than that median.

Fair Value models

Bear ₹37.64 Fair Value ₹50.19 Bull ₹59.37
Price ₹92.00 · Downside -45.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
P/E Multiple ₹37.64 ₹50.19 ₹62.74 63
Residual Income ₹54.90 ₹55.75 ₹59.37 61
Growth-Adj P/E ₹29.45 ₹42.07 ₹54.69 59
All 8 models by family
Earnings-Based
Graham-Dodd ₹15.51 ₹41.27 ₹53.95 51
Lynch FV ₹7.98 ₹11.41 ₹14.83 48
PEG = 1.0 ₹7.98 ₹11.41 ₹14.83 45
Multiples
P/E Multiple ₹37.64 ₹50.19 ₹62.74 63
P/B Multiple ₹295.75 ₹394.34 ₹492.92 55
Asset-Based
NCAV (Graham) ₹46.68 ₹70.73 ₹88.41 52
Economic Profit
Residual Income ₹54.90 ₹55.75 ₹59.37 61
Growth Earnings
Growth-Adj P/E ₹29.45 ₹42.07 ₹54.69 59

Open the full fair value analysis →

Quality Score breakdown

Overall quality 64/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 14
How much profit the company makes from its sales and capital
Quality Growth 25
Are margins and returns getting better?
Cashflow 100
Do the profits arrive as real cash?
Financial strength 100
Debt, balance sheet and risk of trouble
Investment 78
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 37
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 18
Distance to the 52-week high, does not count
New shares 82
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+6.5%
Earnings growth per share plus dividend.
Earnings per share, growth per year+6.5%
Dividend (yield on the price)0.0%

CHEMOPH screens overvalued: fair value 45% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare CHEMO PHARMA LABORATORIES LTD. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 850 stocks

Beats the industry median on 4/7 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 64 · Top 25%
Fair Value upside −45.4% · Bottom 25%
Profitability
Return on assets 2.6% · Top 25%
Operating margin (12 months) 18.7% · Top 25%
Growth and dividend
Revenue growth (quarter YoY) −16.7% · Below median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 1.49× · Cheaper than median
P/S (12 months) 84.05× · Priciest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $957.76 $1,275 +33% vs CHEMOPH
Samsung Biologics Co 207940 1,366,000 KRW 1,552,100 KRW +14% vs CHEMOPH
Vertex Pharmaceuticals Incorporated VRTX $534.20 $587.62 +10% vs CHEMOPH
argenx SE ARGX $947.52 $908.40 −4% vs CHEMOPH
CSL Limited CSL A$199.38 A$186.49 −6% vs CHEMOPH
Moderna, Inc MRNA $206.80 $135.64 −34% vs CHEMOPH
BeOne Medicines AG 6160 HK$244.80 HK$152.92 −38% vs CHEMOPH
Revolution Medicines, Inc RVMD $162.69 $88.78 −45% vs CHEMOPH
Celltrion, Inc 068270 207,500 KRW 74,945 KRW −64% vs CHEMOPH
Royalty Pharma plc RPRX $68.68 $19.01 −72% vs CHEMOPH

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

CHEMO PHARMA LABORATORIES LTD.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "CHEMO PHARMA LABORATORIES LTD. Fair Value". https://www.fairvalue-calculator.com/stock/CHEMOPH

Frequently asked questions

Is CHEMO PHARMA LABORATORIES LTD. (CHEMOPH) overvalued or undervalued?
As of Nov 15, 2026, our model estimates a fair value of ₹50.19 versus a price of ₹92.00, about 45% lower (overvalued).
What is the fair value of CHEMOPH?
Our model-based fair value for CHEMO PHARMA LABORATORIES LTD. is ₹50.19 (as of Nov 15, 2026), built from audited fundamentals. The current price: ₹92.00.
What is the quality score of CHEMOPH?
CHEMO PHARMA LABORATORIES LTD. has a Quality Score of 64/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for CHEMO PHARMA LABORATORIES LTD. (CHEMOPH)?
Our model-based price target is the fair value of ₹50.19 (as of Nov 15, 2026) from 8 valuation models. Cautious scenario ₹37.64, optimistic scenario ₹59.37. It is a calculation from audited fundamentals, not an analyst target.
What is the CHEMO PHARMA LABORATORIES LTD. stock forecast for 2026?
Our models put fair value at ₹50.19, about 45% lower versus a price of ₹92.00 (overvalued). Cautious scenario ₹37.64, optimistic scenario ₹59.37. The calculation is refreshed regularly with new filings.
What is the revenue of CHEMO PHARMA LABORATORIES LTD. (CHEMOPH)?
CHEMO PHARMA LABORATORIES LTD. reported trailing-twelve-month revenue of about ₹2.3M (latest available figure, as of Nov 15, 2026).
What is the intrinsic value of CHEMO PHARMA LABORATORIES LTD. (CHEMOPH)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For CHEMO PHARMA LABORATORIES LTD. it is ₹50.19 per share (as of Nov 15, 2026), against a price of ₹92.00. It is the blended result of 8 valuation models in 5 families (Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is CHEMO PHARMA LABORATORIES LTD. stock overvalued or undervalued in 2026?
As of Nov 15, 2026, CHEMOPH trades above its calculated fair value: price ₹92.00, fair value ₹50.19, a gap of about −45% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CHEMOPH?
No. The price is what the market pays today (₹92.00); the fair value is what the company's own numbers justify (₹50.19). For CHEMO PHARMA LABORATORIES LTD. the two are ₹41.81 per share apart. That gap is exactly why we show both numbers side by side.
How much is CHEMO PHARMA LABORATORIES LTD. worth?
The market values CHEMO PHARMA LABORATORIES LTD. at about ₹196M (market capitalisation, as of Nov 15, 2026). Per share that is ₹92.00; our models calculate a fair value of ₹50.19 per share.
What do the bullish and bearish scenarios say about CHEMOPH?
Our models span a range for CHEMO PHARMA LABORATORIES LTD.: cautious scenario ₹37.64, base ₹50.19, optimistic ₹59.37 per share (as of Nov 15, 2026, price ₹92.00). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of CHEMO PHARMA LABORATORIES LTD. (CHEMOPH)?
Balance-sheet figures for CHEMO PHARMA LABORATORIES LTD. (as of Nov 15, 2026): return on equity −161.9%. They feed the Quality Score of 64/100, which measures business quality independently of the share price.
How far is CHEMOPH from its 52-week high?
CHEMO PHARMA LABORATORIES LTD. trades at ₹92.00, about 37% below its 52-week high of ₹145.75 and 30% above the low of ₹71.01 (as of Nov 18, 2026). Distance from the high says nothing about value: that is what the fair value of ₹50.19 is for.
Which stocks are comparable to CHEMO PHARMA LABORATORIES LTD.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is CHEMO PHARMA LABORATORIES LTD. stock attractive at the current price?
The data as of Nov 15, 2026: price ₹92.00, calculated fair value ₹50.19 (−45%), Quality Score 64/100, from 8 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CHEMOPH calculated?
We run CHEMO PHARMA LABORATORIES LTD. through 8 models from 5 families: Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ₹50.19 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 12.3% above its aggregate fair value. CHEMO PHARMA LABORATORIES LTD. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of CHEMO PHARMA LABORATORIES LTD. (CHEMOPH)?
The closing price on Nov 18, 2026 was ₹92.00. Our model-based fair value is ₹50.19, about 45% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with CHEMO PHARMA LABORATORIES LTD. right now?
The price sits above even our optimistic bull case (₹59.37). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (64/100) and above fair value, neither a clear bargain nor a standout compounder.

Key figures of CHEMO PHARMA LABORATORIES LTD.

How large is the market capitalisation of CHEMO PHARMA LABORATORIES LTD. (CHEMOPH)?
The market capitalisation of CHEMO PHARMA LABORATORIES LTD. is ₹196M (≈ $2.1M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of CHEMO PHARMA LABORATORIES LTD. (CHEMOPH)?
The price-to-sales ratio of CHEMO PHARMA LABORATORIES LTD. is 84.1 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of CHEMO PHARMA LABORATORIES LTD. (CHEMOPH)?
Earnings per share at CHEMO PHARMA LABORATORIES LTD. are ₹−81.48. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of CHEMO PHARMA LABORATORIES LTD. (CHEMOPH)?
The return on equity (ROE) of CHEMO PHARMA LABORATORIES LTD. is −162% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of CHEMO PHARMA LABORATORIES LTD. (CHEMOPH)?
On an EBIT basis the return on assets of CHEMO PHARMA LABORATORIES LTD. is −1.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of CHEMO PHARMA LABORATORIES LTD. (CHEMOPH)?
The operating margin of CHEMO PHARMA LABORATORIES LTD. is 18.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at CHEMO PHARMA LABORATORIES LTD. (CHEMOPH)?
Revenue at CHEMO PHARMA LABORATORIES LTD. is down 16.7% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at CHEMO PHARMA LABORATORIES LTD. (CHEMOPH)?
Earnings per share at CHEMO PHARMA LABORATORIES LTD. are down 84.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does CHEMO PHARMA LABORATORIES LTD. (CHEMOPH) generate?
The free cash flow of CHEMO PHARMA LABORATORIES LTD. is −₹2.8M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch CHEMO PHARMA LABORATORIES LTD. in the live analysis

One click puts CHEMO PHARMA LABORATORIES LTD. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.